NCT02804854View on ClinicalTrials.gov

Sensing Using Neutrophil Activation Probe on the Intensive Therapy Unit

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Lung Disease
Interventions
DRUG

Neutrophil Activation Probe (NAP)

Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).

Trial Locations (2)

EH16 4TJ

Ward 118 Intensive Care, Royal Infirmary of Edinburgh, Edinburgh

EH4 2XU

Western General Hospital, Edinburgh

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

University of Edinburgh

OTHER